Bridgefront Capital, LLC Vaxcyte, Inc. Transaction History
Bridgefront Capital, LLC
- $129 Million
- Q1 2024
A detailed history of Bridgefront Capital, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 6,594 shares of PCVX stock, worth $501,539. This represents 0.35% of its overall portfolio holdings.
Number of Shares
6,594
Previous 3,209
105.48%
Holding current value
$501,539
Previous $201,000
123.88%
% of portfolio
0.35%
Previous 0.16%
Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
268Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$741 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$724 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$584 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$374 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$315 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.51B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...